Projected Sales Volume: Conduit Pharma (CDT)

Brandmark of Conduit Therapeutics (CDT)

Conduit Pharmaceuticals (CDT) generates revenue by licensing therapies for kidney and lung diseases, targeting the multi-billion dollar chronic pathology segment. On GURU.Markets, the company's projected sales are displayed within a sideways corridor, where 0.00 captures the magnitude of this parameter. Demand for such drugs remains stable regardless of GDP, while a strategy of acquiring existing assets minimizes scientific risks.

Company Expected Sales Volume: Conduit Pharmaceuticals (CDT) for 02/21/2024 - 11/14/2026

Conduit Pharmaceuticals Inc (CDT) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Quotes Conduit Pharmaceuticals|CDT - Average Forecast Price
- company stock exchange capitalization indicators:
Market Capitalization Conduit Pharmaceuticals Inc|CDT - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Conduit Pharmaceuticals|CDT - Total Stockholders' Equity|Market Value to Book Value Ratio conduitpharma.com|CDT - Total Business Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Conduit Pharmaceuticals|CDT - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Conduit Pharma|CDT - Company Aggregate Debts|Debts to Book Capitalization Conduit Pharmaceuticals Inc|CDT - Long-Term Debt Volume|Company Current Liabilities Conduit Pharmaceuticals|Quick Liquidity Indicator conduitpharma.com
- company profitability and valuation multiples indicators:
CDT - Final Profit|Expected Profit Conduit Pharmaceuticals|CDT - Market Cap to Net Income|Forward P/E Multiple Conduit Pharmaceuticals Inc.|CDT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Conduit Pharmaceuticals Inc|CDT - Operating profit EBITDA|Earnings per share for the last twelve months Conduit Pharmaceuticals|CDT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months conduitpharma.com|CDT - Net earnings per share growth this year|Earnings growth forecast for next year Conduit Pharmaceuticals
- sales and revenue data:
CDT - Revenue and Sales Volume|Projected Sales Volume Conduit Pharmaceuticals|CDT - Market Cap to Revenue|Forward P/S Multiple Conduit Pharmaceuticals Inc
Comprehensive company analysis:Conduit Pharmaceuticals
Brand item of Conduit Therapeutics

Assessing the margin of safety for Conduit Pharmaceuticals (CDT) requires an analysis of expected cash flows from asset realization. This indicator captures market expectations for future revenues, reflecting the capitalization of potential contracts. The trend in the company's planned sales allows investors to promptly determine the degree of business undervaluation. The upward trajectory confirms management's efficiency in selecting molecules for licensing. This verifies the sustainability of the labless model of reselling rights to pharmaceutical behemoths.

Main competitors

Company Future Sales Volume TVTX (Travere Therapeutics)|ARDX - Company Expected Sales Volume|Projected Sales Volume PROK (ProKidney)|AKBA - Company Future Sales Volume|TVRD - Company Projected Revenue|Company Expected Sales Volume DiaMedica Corp|Unicycive Therapeutics (UNCY) - Company Projected Revenue|Company Revenue Forecast RMTI|CVKD (Cadrenal Therapeutics, Inc.) - Projected Sales Volume|Company Revenue Forecast CALT (Calliditas)|Company Future Sales Volume RNLX (Renalytix AI)|Projected Sales Volume zyversa.com (ZVSA)